The Impact of Statins on FGF–2—Stimulated Human Umbilical Vein Endothelial Cells

References

• . Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995;57:791–804
   PubMed Web of Science ®Google Scholar
• . Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem. 2007;40(9–10):575–584
   PubMed Web of Science ®Google Scholar
• . Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118
   PubMed Web of Science ®Google Scholar
• . Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb. 2003;10(2):63–71
   PubMedGoogle Scholar
• . Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1(1):31–39
   PubMed Web of Science ®Google Scholar
• . Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science. 2010;327(5961):46–50
   PubMed Web of Science ®Google Scholar
• . Dainese E, Oddi S, Bari M, Maccarrone M. Modulation of the endo-cannabinoid system by lipid rafts. Curr Med Chem. 2007;14(25):2702–2715
   PubMedGoogle Scholar
• . Li PL, Zhang Y, Yi F. Lipid raft redox signaling platforms in endothelial dysfunction. Antioxid Redox Signal. 2007;9(9):1457–1470
   PubMedGoogle Scholar
• . Ribatti D, Vacca A, Rusnati M, Presta M. The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine Growth Factor Rev. 2007;18(3–4):327–334
   PubMed Web of Science ®Google Scholar
• . Murakami M, Elfenbein A, Simons M. Non-canonical fibroblast growth factor signalling in angiogenesis. Cardiovasc Res. 2008;78(2):223–231
   PubMed Web of Science ®Google Scholar
• . Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med. 2002;6(10):483–489
   Google Scholar
• . Vincent L, Chen W, Hong L, . Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett. 2001;495(3):159–166
   PubMed Web of Science ®Google Scholar
• . Seelenmeyer C, Stegmayer C, Nickel W. Unconventional secretion of fibroblast growth factor 2 and galectin-1 does not require shedding of plasma membrane-derived vesicles. FEBS Lett. 2008;582(9):1362–1368
   PubMedGoogle Scholar
• . Matsumoto T, Turesson I, Book M, Gerwins P, Claesson-Welsh L. p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis. J Cell Biol. 2002;156(1):149–160
   PubMedGoogle Scholar
• . Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52(11):2745–2756
   PubMed Web of Science ®Google Scholar
• . Gillies RJ, Didier N, Denton M. Determination of cell number in monolayer cultures. Anal Biochem. 1986;159(1):109–113
   PubMedGoogle Scholar
• . Cheung DT, Nimni ME. Mechanism of crosslinking of proteins by glutaraldehyde II. Reaction with monomeric and polymeric collagen. Connect Tissue Res. 1982;10(2):201–216
   PubMed Web of Science ®Google Scholar
• . Schaefer CA, Kuhlmann CR, Gast C, . Statins prevent oxidized low-density lipoprotein- and lysophosphatidylcholine-induced proliferation of human endothelial cells. Vascul Pharmacol. 2004;41(2):67–73
   PubMed Web of Science ®Google Scholar
• . Chu CL, Buczek-Thomas JA, Nugent MA. Heparan sulphate proteoglycans modulate fibroblast growth factor-2 binding through a lipid raft-mediated mechanism. Biochem J. 2004;379(Pt 2):331–341
   PubMed Web of Science ®Google Scholar
• . Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem. 1989;182(1):16–19
   PubMed Web of Science ®Google Scholar
• . Durrington P. Dyslipidaemia. Lancet. 2003;362(9385):717–731
   PubMed Web of Science ®Google Scholar
• . Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004;109(23 Suppl 1):112–117
   Google Scholar
• . Ohara P, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91(6):2546–2551
   PubMed Web of Science ®Google Scholar
• . Azadzoi KM, Saenz de Tejada I. Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol. 1991;146(1):238–240
   PubMedGoogle Scholar
• . Böger RH, Bode-Böger SM, Szuba A, . Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98(18):1842–1847
   PubMed Web of Science ®Google Scholar
• . Li X, Liu L, Tupper JC, . Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem. 2002;277(18):15309–15316
   PubMedGoogle Scholar
• . Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res. 2005;97(12):1232–1235
   PubMedGoogle Scholar
• . Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke. 2004;35(11 Suppl 1):2708–2711
   PubMedGoogle Scholar
• . Hillyard DZ, Nutt CD, Thomson J, . Statins inhibit NK cell cytotoxicity by membrane raft depletion rather than inhibition of isoprenylation. Atherosclerosis. 2007;191(2):319–325
   PubMedGoogle Scholar
• . Skaletz-Rorowski A, Kureishi Y, Shiojima I, Walsh K. The pro- and anti-angiogenic effects of statins. Semin Vasc Med. 2004;4(4):395–400
   PubMedGoogle Scholar
• . Kureishi Y, Luo Z, Shiojima I, . The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6(9):1004–1010
   PubMed Web of Science ®Google Scholar
• . Gelosa P, Cimino M, Pignieri A, Tremoli E, Guerrini U, Sironi L. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag. 2007;3(5):567–577
   PubMedGoogle Scholar
• . Ii M, Losordo DW. Statins and the endothelium. Vascul Pharmacol. 2007;46(1):1–9
   PubMed Web of Science ®Google Scholar
• . Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21(11):1712–1719
   PubMed Web of Science ®Google Scholar
• . Shiota M, Hikita Y, Kawamoto Y, . Pravastatin-induced proangiogenic effects depend upon extracellular FGF-2. J Cell Mol Med. 2012;16(9):2001–2009
   PubMedGoogle Scholar
• . Sindermann JR, Schmidt A, Breithardt G, Buddecke E. Lovastatin controls signal transduction in vascular smooth muscle cells by modulating phosphorylation levels of mevalonate-independent pathways. Basic Res Cardiol. 2001;96(3):283–289
   PubMedGoogle Scholar
• . Bulbulia R, Armitage J. Does the benefit from statin therapy extend beyond 5 years? Curr Atheroscler Rep. 2013;15(2):297
   PubMedGoogle Scholar
• . Stokić E. Modern statin therapy in clinical practice: the lower the better. Srp Arh Celok Lek. 2013;141(1–2):104–108
   PubMedGoogle Scholar
• . Ference BA, Mahajan N. The role of early LDL lowering to prevent the onset of atherosclerotic disease. Curr Atheroscler Rep. 2013;15(4):312
   PubMed Web of Science ®Google Scholar
• . Mustanoja S, Strbian D, Putaala J, . Association of prestroke statin use and lipid levels with outcome of intracerebral hemorrhage. Stroke. 2013;44(8):2330–2332
   PubMed Web of Science ®Google Scholar
• . Asakage M, Tsuno NH, Kitayama J, . 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest. Anticancer Drugs. 2004;15(6):625–632
   PubMedGoogle Scholar
• . Vincent L, Soria C, Mirshahi F, . Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol. 2002;22(4):623–629
   PubMedGoogle Scholar
• . Schaefer CA, Kuhlmann CR, Weiterer S, . Statins inhibit hypoxia-induced endothelial proliferation by preventing calcium-induced ROS formation. Atherosclerosis. 2006;185(2):290–296
   PubMedGoogle Scholar
• . Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002;105(6):739–745
   PubMed Web of Science ®Google Scholar
• . Chen J, Chen L, Wang G, Tang H. Cholesterol-dependent and—independent CD40 internalization and signaling activation in cardiovascular endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27(9):2005–2013
   PubMedGoogle Scholar
• . Wu H, Mahmood A, Lu D, . Attenuation of astrogliosis and modulation of endothelial growth factor receptor in lipid rafts by simvastatin after traumatic brain injury. J NeuroSurg. 2010;113(3):591–597
   PubMedGoogle Scholar
• . Hori Y, Kikuchi A, Isomura M, . Post-translational modifications of the C-terminal region of the rho protein are important for its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins. Oncogene. 1991;6(4):515–522
   PubMedGoogle Scholar
• . Lowy DR, Willumsen BM. Protein modification: new clue to Ras lipid glue. Nature. 1989;341(6241):384–385
   PubMedGoogle Scholar
• . Melkonian KA, Ostermeyer AG, Chen JZ, Roth MG, Brown DA. Role of lipid modifications in targeting proteins to detergent-resistant membrane rafts. Many raft proteins are acylated, while few are prenylated. J Biol Chem. 1999;274(6):3910–3917
   PubMed Web of Science ®Google Scholar
• . Park HJ, Kong D, Iruela-Arispe L, Begly U, Tang D, Galper JB. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res. 2002;91(2):143–150
   PubMed Web of Science ®Google Scholar
• . Maher PA. Nuclear translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J Cell Biol. 1996;134(2):529–536
   PubMedGoogle Scholar
• . Renko M, Quarto N, Morimoto T, Rifkin DB. Nuclear and cytoplasmic localization of different basic fibroblast growth factor species. J Cell Physiol. 1990;144(1):108–114
   PubMed Web of Science ®Google Scholar
• . Bonnet H, Filhol O, Truchet I, . Fibroblast growth factor-2 binds to the regulatory b subunit of CK2 and directly stimulates CK2 activity toward nucleolin. J Biol Chem. 1996;271(40):24781–24787
   PubMed Web of Science ®Google Scholar
• . Pederson T. Growth factors in the nucleolus? J Cell Biol. 1998;143(2):279–281
   PubMedGoogle Scholar